Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1995 Aug 5;311(7001):351–356. doi: 10.1136/bmj.311.7001.351

Using decision analysis to compare policies for antenatal screening for Down's syndrome.

J Fletcher 1, N R Hicks 1, J D Kay 1, P A Boyd 1
PMCID: PMC2550427  PMID: 7640539

Abstract

OBJECTIVE--To compare different screening policies for Down's syndrome across a broad range of outcomes, using decision analysis, with particular reference to the role of maternal serum testing. DESIGN--A decision tree was used to combine data from local sources and the medical literature to predict the likely frequency of several outcomes. Sensitivity analyses were used to test the robustness of the conclusions drawn. SETTING--Oxfordshire Health Authority. MAIN OUTCOME MEASURES--Live births with and without Down's syndrome; miscarriages with Down's syndrome; cases of Down's syndrome detected antenatally; amniocenteses performed (and associated miscarriages); direct NHS screening costs; number of women offered screening. RESULTS--Screening policies for Down's syndrome that include serum testing can produce better population outcomes than programmes that do not. Each option for screening for Down's syndrome that we considered had significant drawbacks. In Oxfordshire, offering serum testing to women of all ages would prevent the birth of approximately one more baby with Down's syndrome per year than would a policy of screening for women aged 30 years or more. The cost of preventing this one extra Down's birth would be one or two normal babies lost after amniocentesis, 4500 blood tests for young women (with the associated anxiety and counselling), approximately 200 false positive serum test results and amniocenteses (with the associated anxiety and distress), and 90,000 pounds for the extra tests, counselling, and amniocenteses. Opinions are divided as to which policy is the better option for the population. CONCLUSIONS--Decision analysis is a useful tool for determining the likely consequences of different policy options across a broad range of outcomes. This focuses debate and decision making on outcomes of care, which in turn makes it clear that the choice of screening programme for Down's syndrome depends on the relative importance ascribed to the different outcomes. If individuals' values vary widely it may be impossible to find one screening policy that meets the needs of all pregnant women.

Full text

PDF
354

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ager R. P., Oliver R. W. Screening for Down syndrome. Lancet. 1987 Sep 5;2(8558):566–567. doi: 10.1016/s0140-6736(87)92949-7. [DOI] [PubMed] [Google Scholar]
  2. Bhatti N., Mackie A. Antenatal screening for Down's syndrome. BMJ. 1992 Sep 26;305(6856):770–771. doi: 10.1136/bmj.305.6856.770-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Connor M. Biochemical screening for Down's syndrome. BMJ. 1993 Jun 26;306(6894):1705–1706. doi: 10.1136/bmj.306.6894.1705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cuckle H. Maternal serum screening policy for Down's syndrome. Lancet. 1992 Sep 26;340(8822):799–799. doi: 10.1016/0140-6736(92)92349-k. [DOI] [PubMed] [Google Scholar]
  5. Haddow J. E., Palomaki G. E., Knight G. J., Williams J., Pulkkinen A., Canick J. A., Saller D. N., Jr, Bowers G. B. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med. 1992 Aug 27;327(9):588–593. doi: 10.1056/NEJM199208273270902. [DOI] [PubMed] [Google Scholar]
  6. Kassirer J. P. Incorporating patients' preferences into medical decisions. N Engl J Med. 1994 Jun 30;330(26):1895–1896. doi: 10.1056/NEJM199406303302611. [DOI] [PubMed] [Google Scholar]
  7. Keatinge R., Rogers C. Serum screening for Down's syndrome. Existing tests not good enough. BMJ. 1993 Aug 21;307(6902):501–502. doi: 10.1136/bmj.307.6902.501-c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Keatinge R. Screening for Down's syndrome. Lancet. 1992 Oct 24;340(8826):1034–1034. doi: 10.1016/0140-6736(92)93042-l. [DOI] [PubMed] [Google Scholar]
  9. Macri J. N., Kasturi R. V., Krantz D. A., Cook E. J. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age. Obstet Gynecol. 1991 Jun;77(6):963–965. [PubMed] [Google Scholar]
  10. Macri V. J., Clark R. Antenatal screening for Down's syndrome. BMJ. 1992 Sep 26;305(6856):768–771. doi: 10.1136/bmj.305.6856.768-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Marteau T. M. Psychological consequences of screening for Down's syndrome. BMJ. 1993 Jul 17;307(6897):146–147. doi: 10.1136/bmj.307.6897.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Marteau T. M., Slack J., Kidd J., Shaw R. W. Presenting a routine screening test in antenatal care: practice observed. Public Health. 1992 Mar;106(2):131–141. doi: 10.1016/s0033-3506(05)80390-7. [DOI] [PubMed] [Google Scholar]
  13. Milner P. Unsettling times for public health. J Public Health Med. 1994 Mar;16(1):1–3. doi: 10.1093/oxfordjournals.pubmed.a042908. [DOI] [PubMed] [Google Scholar]
  14. Oliver R. W., Ager R. P. Screening for Down syndrome. Lancet. 1988 Mar 26;1(8587):709–710. doi: 10.1016/s0140-6736(88)91515-2. [DOI] [PubMed] [Google Scholar]
  15. Oxman A. D., Sackett D. L., Guyatt G. H. Users' guides to the medical literature. I. How to get started. The Evidence-Based Medicine Working Group. JAMA. 1993 Nov 3;270(17):2093–2095. [PubMed] [Google Scholar]
  17. Phillips O. P., Elias S., Shulman L. P., Andersen R. N., Morgan C. D., Simpson J. L. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Obstet Gynecol. 1992 Sep;80(3 Pt 1):353–358. [PubMed] [Google Scholar]
  18. Reynolds T. M., Nix A. B., Dunstan F. D., Dawson A. J. Age-specific detection and false-positive rates: an aid to counseling in Down syndrome risk screening. Obstet Gynecol. 1993 Mar;81(3):447–450. [PubMed] [Google Scholar]
  19. Shackley P., McGuire A., Boyd P. A., Dennis J., Fitchett M., Kay J., Roche M., Wood P. An economic appraisal of alternative pre-natal screening programmes for Down's syndrome. J Public Health Med. 1993 Jun;15(2):175–184. [PubMed] [Google Scholar]
  20. Sheldon T. A., Simpson J. Appraisal of a new scheme for prenatal screening for Down's syndrome. BMJ. 1991 May 11;302(6785):1133–1136. doi: 10.1136/bmj.302.6785.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Spencer K., Coombes E. J., Mallard A. S., Ward A. M. Free beta human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers. Ann Clin Biochem. 1992 Sep;29(Pt 5):506–518. doi: 10.1177/000456329202900504. [DOI] [PubMed] [Google Scholar]
  22. Statham H., Green J. Serum screening for Down's syndrome: some women's experiences. BMJ. 1993 Jul 17;307(6897):174–176. doi: 10.1136/bmj.307.6897.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tabor A., Philip J., Madsen M., Bang J., Obel E. B., Nørgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet. 1986 Jun 7;1(8493):1287–1293. doi: 10.1016/s0140-6736(86)91218-3. [DOI] [PubMed] [Google Scholar]
  24. Thornton J. G., Lilford R. J., Johnson N. Decision analysis in medicine. BMJ. 1992 Apr 25;304(6834):1099–1103. doi: 10.1136/bmj.304.6834.1099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wald N. J., Cuckle H. S., Densem J. W., Nanchahal K., Royston P., Chard T., Haddow J. E., Knight G. J., Palomaki G. E., Canick J. A. Maternal serum screening for Down's syndrome in early pregnancy. BMJ. 1988 Oct 8;297(6653):883–887. doi: 10.1136/bmj.297.6653.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wald N. J., Kennard A., Densem J. W., Cuckle H. S., Chard T., Butler L. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. BMJ. 1992 Aug 15;305(6850):391–394. doi: 10.1136/bmj.305.6850.391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wald N., Wald K., Smith D. The extent of Down's syndrome screening in Britain in 1991. Lancet. 1992 Aug 22;340(8817):494–494. doi: 10.1016/0140-6736(92)91822-p. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES